
Abcam acquires rights to over 700 Roche products in new licensing deal
pharmafile | January 22, 2018 | News story | Sales and Marketing | Abcam, Roche, partnership, pharma
Roche has entered a licensing agreement Abcam which gives the British biotech exclusive access to the marketing rights for 760 of the Swiss pharma giant’s products, all of which are for research use only (RUO).
The full range of products represents the complete portfolio of Spring Bioscience Corporation, a California-based biotech that Roche acquired in 2007, and includes 243 antibodies for use in rabbits, in addition to more than 500 other antibodies.
As part of the deal, Abcam will have the rights to any future antibodies developed by Spring which Roche decides to commercialise for an initial period of 10 years. Roche retains the right to use antibodies for internal research and as companion diagnostic tools.
Abcam will begin commercialising and selling the acquired antibodies from 21 February.
The deal marks the latest in a series of moves by Abcam to expand its portfolio, which now includes more than 120,000 products. Since 2011, the biotech has made a number of acquisitions to this end, including AxioMx, Ascent Scientific, Epitomics, Firefly Bioworks and MitoSciences.
Matt Fellows
Related Content

Landmark Bio and Mass General Brigham partner to accelerate translational CGT therapies
Landmark Bio and Mass General Brigham in the US have entered a new strategic collaboration …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …






